Security researchers found a zero-click vulnerability in Microsoft 365 Copilot.
The vulnerability, called 'EchoLeak,' lets attackers 'automatically exfiltrate sensitive and proprietary information' from Microsoft 365 Copilot without knowledge of the user, according to findings from Aim Labs.
An attacker only needs to send their victim a malicious prompt injection disguised as a normal email, which covertly instructs Copilot to pull sensitive information from a user's account.
Microsoft has since fixed the critical flaw and given it the identifier CVE-2025-32711. It also hasn't been exploited in the wild.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
6 minutes ago
- Bloomberg
Retailers Seen Using Stablecoins to Push Back Against Card Fees
Stablecoins have become one of the hottest buzzwords in the world of finance as of late with US lawmakers on the cusp of passing the first guidelines for mainstream use of the cryptocurrencies designed to mirror the dollar. Everyone from banks to securities firms to fintech startups are experimenting with the tokens as a means of making payment systems faster and cheaper. That apparently even includes Walmart Inc. and even Inc., the Wall Street Journal reported Friday.
Android Authority
29 minutes ago
- Android Authority
The Vivoactive 6 is the best and worst thing to happen to the Garmin Venu series
Kaitlyn Cimino / Android Authority I've been testing Garmin's Vivoactive and Venu series for generations, and in the past, each line clearly catered to distinct user needs. The Vivoactive line was my go-to recommendation for budget-conscious athletes. The Venu stood as Garmin's best option for a rounded smartwatch experience. With the release of the Garmin Vivoactive 6, however, the line between the two series feels blurrier than ever, and for the first time, I'm struggling to distinguish between them clearly. Would you prefer Garmin's Vivoactive 6 or Venu 3? 0 votes Garmin Vivoactive 6 NaN % Garmin Venu 3 NaN % Neither NaN % Halfway through testing the Vivoactive 6, I realized that the differences between it and the Venu 3 are far less clear than I expected. The two watches each boast an AMOLED display and utilize predictably similar design language. Both feature sleek, lightweight polymer builds, comfortable, quick-release silicone straps, and 5ATM water resistance. I wear either one without a second thought about durability or comfort. The Vivoactive 6 is smaller and lighter, with an aluminum bezel instead of a stainless steel one, but I still find it a relatively elegant accessory, just like the Venu 3. Kaitlyn Cimino / Android Authority Under the hood, both watches deliver over a week of battery life, so I'm never left stranded with a dead device, along with music storage, NFC support, and access to Garmin's Connect IQ app store. On top of that, they share nearly identical core health and fitness tracking features. The Venu 3 does include a newer heart rate sensor and a barometric altimeter, but in my testing, both devices proved remarkably accurate compared to my chest strap. Kaitlyn Cimino / Android Authority On both devices, users will find advanced sleep tracking, SpO2 monitoring, robust fitness tracking toolkits, and highly reliable built-in GPS. Each also offers Garmin's full suite of safety and tracking features, Find My Phone and Watch, sleep coach and nap detection, and Garmin-specific favorites like Body Battery and Morning Report. In short, both cover all the bases. Garmin is closing the gap between Vivoactive and Venu lineups, leaving shoppers with less differentiation. This overlap raises concerns about product line differentiation and, for me, serves as a knock against the Venu line. The Vivoactive 6 is priced much lower at $299 but includes a variety of features that were once exclusive to the Venu series. The Venu 3, meanwhile, asks shoppers to drop $499. That's a hard sell when the Vivoactive 6 provides a comparable experience at a more accessible price point. The cheaper device also packs in a few training-specific tools not found on the Venu, like extra sport modes, route and course tracking, Smart Wake, and daily suggested walking workouts. Kaitlyn Cimino / Android Authority Of course, that isn't to say the Vivoactive 6 has everything shoppers may like about the Venu. I was most disappointed to see the ECG app is still missing from the Vivoactive 6 (due to the older heart rate sensor). There's also the extra button, metallic detailing, and microphone/speaker package for voice assistance and Bluetooth phone call support. Yet surely those differences don't equate to a $200 markup, do they? Kaitlyn Cimino / Android Authority The positive spin is that the Vivoactive 6's feature set and proximity to the Venu 3's offerings could spark evolution for the Venu series. To maintain the line's premium status, Garmin needs to reposition the lineup as a true smartwatch. I, for one, would love to see LTE support and expanded third-party app integrations. This would make the Venu series more competitive with devices like the Pixel Watch 3 or Apple Watch. My hope is that the Venu line will expand its smart features to maintain its premium status. All in all, the Garmin Vivoactive 6 and Venu 3 are both great watches, but the line between them is getting blurry. As the Vivoactive keeps leveling up, the Venu has to evolve too, not just in price, but in purpose. Garmin doesn't need to scrap either lineup. The company just needs to give shoppers clearer reasons to choose one over the other.
Forbes
29 minutes ago
- Forbes
5 Stocks To Buy As The Stock Market Nears All-Time Highs
The stock market's remarkable recovery from earlier 2025 volatility has investors questioning whether it's still a good time to buy. The S&P 500 hit 6,000 for the first time since February following strong economic data. Subsequently, it fell to a low of 4,910 in April due to Tariff concerns and investor pessimism as Trump rolled out his new economic plans. In May, it bounced back, and despite ongoing Tariff concerns, the S&P 500 closed out the Month with a gain of more than 6%, its best monthly performance since November 2023. Current market conditions present both opportunities and challenges for investors. While some analysts worry about overvaluation, earnings estimates have been revised to 7% growth for 2025, suggesting markets are no longer priced for an adverse outcome. The recent recovery from the spring market correction demonstrates the resilience of quality companies with strong fundamentals. The methodology for selecting these five stocks focused on companies with compelling growth prospects, strong competitive positions and the ability to thrive in various market conditions. I analyzed quantitative metrics, including revenue growth, profit margins and valuation ratios, while also considering qualitative factors such as market leadership, innovation capabilities and long-term strategic positioning. These selections represent diverse sectors that are well-positioned to benefit from current economic trends. Tesla remains the world's leading electric vehicle manufacturer, with expanding operations in energy storage, solar panels and autonomous driving technology. The company has successfully scaled production across multiple global facilities while maintaining industry-leading margins. Despite recent volatility stemming from tensions around Elon Musk's involvement in the U.S. Department of Government Efficiency (DOGE), which temporarily cut $152 billion from Tesla's market capitalization, the underlying business fundamentals remain strong, with growing EV adoption worldwide. Tesla's market leadership in the rapidly expanding electric vehicle (EV) sector positions it perfectly for long-term growth. The company's vertical integration strategy, from battery production to charging infrastructure, creates substantial competitive advantages. Recent developments in autonomous driving technology and energy storage solutions provide multiple revenue streams beyond traditional automotive sales. The temporary price decline from Elon Musk's entanglement with politics and perhaps declining mental stability creates an attractive entry point for long-term investors. Tesla's global expansion, particularly in emerging markets, combined with decreasing battery costs and improving production efficiency, suggests strong earnings growth potential. The company's innovation pipeline, which includes robotaxi services and energy grid solutions, offers significant upside beyond its current valuations. Microsoft stands as one of the world's most valuable companies, dominating cloud computing through Azure, productivity software via Office 365 and emerging AI technologies. The company has successfully transitioned from traditional software licensing to subscription-based services, creating predictable recurring revenue streams. Microsoft shares advanced significantly in early May, with AI developments reigniting investor interest. Microsoft's diversified business model provides stability and growth across multiple technology sectors. The company's leadership in cloud computing continues to expand as enterprises accelerate their digital transformation initiatives. Azure's growth trajectory, combined with Microsoft's early integration of AI across its product suite, positions the company perfectly for the next wave of technology. Microsoft recently secured a significant deal to bring 1 million Copilot users on board from a single enterprise client, potentially generating over $350 million annually. This adds momentum to its AI strategy, following strong Q3 earnings and record-high share prices. With Azure growth holding steady and demand for AI-integrated tools on the rise, the deal reinforces Microsoft's position as a market leader. At the same time, the stock trades at a premium, continued execution in cloud and AI could justify the valuation, and support further upside. Palantir specializes in big data analytics and artificial intelligence platforms, serving government agencies and commercial enterprises. The stock has surged nearly 75% this year, leading the Nasdaq 100's constituents so far in 2025, driven by expanding federal government contracts and growing commercial adoption. The company's unique position in data integration and analysis creates substantial competitive moats. Palantir's government contracts provide stable, long-term revenue streams with high switching costs due to the mission-critical nature of their platforms. The company's work for the federal government has grown substantially, creating predictable cash flows that support aggressive growth investments. The expanding commercial segment demonstrates Palantir's ability to monetize its technology beyond government applications. The company's AI and machine learning capabilities position it perfectly for the current technology cycle. As organizations increasingly rely on data-driven decision making, Palantir's platforms become essential infrastructure. The high barriers to entry in this specialized market, combined with strong customer retention rates, suggest sustainable competitive advantages that justify premium valuations. Johnson & Johnson represents one of the world's largest healthcare conglomerates, with diversified operations spanning pharmaceuticals, medical devices and consumer products. The company sustains a broad economic moat through outstanding cash flow generation, a growing research pipeline, and multiple revenue sources. Recent strategic acquisitions, including the $14.6 billion purchase of Intra-Cellular, a biopharmaceutical business, demonstrate ongoing portfolio optimization. Johnson & Johnson's defensive characteristics make it an ideal holding during market volatility, while its pharmaceutical pipeline provides significant growth potential. The company's consistent dividend payments, supported by strong cash flows, offer income stability that's particularly attractive in uncertain economic environments. J&J's global reach and diversified product portfolio provide resilience against regional economic downturns. The healthcare sector's demographic tailwinds, driven by aging populations worldwide, create sustained demand for Johnson & Johnson's products and services. The company's strong research and development capabilities, combined with strategic acquisitions, continuously refresh its product pipeline. J&J's excellent credit rating and financial flexibility enable continued investment in growth opportunities while maintaining shareholder returns. HIMS & Hers operates a direct-to-consumer telemedicine platform, offering personalized healthcare solutions that include treatments for hair loss, sexual wellness, mental health and skincare. The company reported a significant increase in net income for the fourth quarter, generating $26 million in net income, up from $5 million in the same period last year. The platform's subscription-based model creates recurring revenue streams with high customer lifetime value. The digital healthcare revolution accelerated by the pandemic has created permanent behavioral changes in how consumers access healthcare services. HIMS capitalizes on this trend by offering convenient and affordable alternatives to traditional healthcare delivery. The company's direct-to-consumer model eliminates intermediaries, improving margins while reducing costs for patients. HIMS addresses large, underserved markets where traditional healthcare often fails to provide adequate solutions. The company's focus on stigmatized conditions creates intense customer loyalty and reduces price sensitivity. Expanding product offerings and geographic reach provide multiple growth vectors, while the subscription model ensures predictable revenue growth. The digital-first approach positions HIMS perfectly for the future of personalized healthcare delivery. Bottom Line These five stocks represent compelling opportunities as markets near all-time highs, each offering unique advantages for different investor profiles. Tesla provides exposure to the electric vehicle (EV) revolution, Microsoft offers stability with AI growth, Palantir captures the data analytics boom, Johnson & Johnson delivers defensive income with growth potential, and HIMS capitalizes on the digital healthcare transformation. While market timing remains uncertain, these quality companies with strong competitive positions and compelling growth prospects offer attractive risk-adjusted returns for long-term investors navigating today's elevated market levels.
